Changes in the renal function
The mean eGFR among the 169 HCM patients with AF at baseline was 54 ± 18
mL/min/1.73 m2. One hundred and six (44%) of 169
patients had an eGFR of less than 60 mL/min/1.73 m2.
After a propensity score matching, the baseline eGFR was 55.0 ± 16.3
mL/min/1.73 m2 in the ablation group and 55.7 ± 13.9
mL/min/1.73 m2 in the control group (P=0.83). The
number of patients in each CKD stage was similar between the two groups
and the prevalence of an eGFR<60 mL/min/1.73
m2 at baseline was 67% in the ablation group and 56%
in the control group (P=0.28) (Table 1). The changes in the eGFR during
the study in both groups are shown in Figure 3. In the control group,
the eGFR significantly decreased from baseline to three months (55.7 ±
13.9 to 52.1 ± 12.8 mL/min/1.73 m2, P<0.01)
and from baseline to one year (55.7 ± 13.9 to 50.5 ± 13.5 mL/min/1.73
m2, P<0.01) after the study enrollment. On
the other hand, the eGFR in the ablation group remained unchanged during
the study period both from baseline to three months (55.0 ± 16.3 to 55.3
± 16.4 mL/min/1.73 m2, P=0.94) and from baseline to
one year (55.0 ± 16.3 to 55.0 ± 15.7 mL/min/1.73 m2,
P=1.00) after the ablation. The changes in the eGFR from baseline to
three months and one year after the study enrollment were similar
between the two groups (P=0.49). A comparison of the ΔeGFR between the
two groups is shown in Figure 4. The ΔeGFR in the ablation group was
significantly smaller than that in the control group (0 ± 7.6 vs. -5.2 ±
9.1 mL/min/1.73 m2, P<0.01). In the ablation
group, the ΔeGFR tended to be smaller in the patients with persistent AF
than in those with PAF (1.7 ± 7.4 vs. -2.1 ± 7.4 mL/min/1.73
m2, P=0.10).